Seth ettenberg unum therapeutics
Web3 Mar 2024 · In addition, the company’s chief scientific officer, Seth Ettenberg, has resigned. He is joining BlueRock Therapeutics as their chief scientific officer. The ACTR707 ATTCK-20-03 trial evaluated ACTR7078 in combination with Genentech and Biogen’s Rituxan (rituximab) in relapsed/refractory non-Hodgkin lymphoma. Web8 Dec 2024 · Author links open overlay panel Taylor Hickman BS * 1 Adrianna Graziano * 1 Katie O'Callaghan PhD * 1 Ryan Boomer BA * 1 Eugene Choi MS * 1 Allison Nelson BS * 1 Greg Motz PhD * 1 Jessica Sachs MD * 1 Birgit Schultes PhD * 1 Seth Ettenberg PhD 2 Tooba Cheema PhD * 1
Seth ettenberg unum therapeutics
Did you know?
WebSeth is Chief Scientific Officer at BlueRock Therapeutics. Prior to joining BlueRock, Dr. Ettenberg was a founding member of the Unum Therapeutics team, where he served as Chief Scientific Officer. In this role, Dr. Ettenberg built and led teams across the organization that brought several novel cellular therapies from invention to clinical testing. Web15 Aug 2024 · BOXR1030 is a first-in-class engineered cell therapy identified from a screen of > 100 bolt-on transgenes, composed of a humanized GPC3-targeting CAR and glutamic …
WebSeth Ettenberg. Chief Scientific Officer at BlueRock Therapeutics. Location: Greater Boston Area. Seth is Chief Scientific Officer at BlueRock Therapeutics. Prior to joining BlueRock, … WebSeth Ettenberg, Ph.D., is the current President and CEO of BlueRock Therapeutics. Seth served as Chief Scientific Officer at BlueRock from 2024 - 2024. Prior to joining BlueRock , …
Web3 Mar 2024 · CAMBRIDGE, Mass., March 03, 2024 (GLOBE NEWSWIRE) -- BlueRock Therapeutics, LP today announced the addition of Seth Ettenberg, Ph.D. to the company’s senior leadership team. In his role as Chief ... WebSeth Ettenberg, PhD, is the current President and CEO of BlueRock Therapeutics. Seth served as Chief Scientific Officer at BlueRock from 2024 – 2024. Prior to joining BlueRock, …
WebSeth A. Ettenberg's 50 research works with 1,827 citations and 4,280 reads, including: BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti ...
Web9 Jun 2024 · Seth Ettenberg, PhD, is the current President and CEO of BlueRock Therapeutics. Seth served as Chief Scientific Officer at BlueRock from 2024 – 2024. Prior to joining BlueRock, Seth was a founding member of the Unum Therapeutics team, where he served as Chief Scientific Officer. stand little chanceWebSeth Ettenberg is a Strategic Advisor at Manifold Bio, and they have also served as the Chief Scientific Officer at Unum Therapeutics, Oncology Biotherapeutics Head at the … personal record at a bank for short crosswordWeb9 Nov 2024 · For almost a decade, Ettenberg ran a research team at NIBR, and became head of oncology biotherapeutics in Cambridge. In 2014, Ettenberg was a founding member of the Unum Therapeutics team, where he served as Chief Scientific Officer. In this role, he built and led teams that brought several novel cellular therapies from invention to clinical ... stand lights musicWeb13 Aug 2024 · As Seth will describe we expect to advance BOXR1030 towards clinical trials to treat liver and lung cancers. We're excited by the ability of ACTR and BOXR to generate … personal recipe softwareWeb1 Nov 2024 · Unum Therapeutics uses its proprietary Antibody-Coupled T cell Receptor (ACTR) technology in combination with tumor-targeting antibodies, to activate the body’s … stand lineWeb3 Mar 2024 · CAMBRIDGE, Mass., March 03, 2024 (GLOBE NEWSWIRE) -- BlueRock Therapeutics, LP today announced the addition of Seth Ettenberg, Ph.D. to the company’s … personalrechtliche themenWebSeth A Ettenberg The Antibody-Coupled T-cell Receptor (ACTR) platform is a universal engineered T cell therapy developed to mediate anti-tumor activity in combination with … personal recipe book